Compare DCX & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCX | INDP |
|---|---|---|
| Founded | 2009 | 2000 |
| Country | China | United States |
| Employees | 1389 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5M | 5.2M |
| IPO Year | N/A | 2021 |
| Metric | DCX | INDP |
|---|---|---|
| Price | $2.21 | $1.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 121.3K | 32.8K |
| Earning Date | 05-14-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.27 |
| 52 Week High | $5.68 | $13.24 |
| Indicator | DCX | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 25.62 |
| Support Level | $2.02 | N/A |
| Resistance Level | $2.22 | $2.08 |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 40.45 | 1.89 |
Digital Currency X Technology Inc, formerly Chijet Motor Company Inc is engaged in the development, manufacture, sales, and service of new energy vehicles (NEV), hybrid vehicles and traditional fuel vehicles in China. New energy vehicles refer to plug-in electric vehicles, including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans. The company generates all of its revenue from PRC.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.